close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Dyne Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN HTGC
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today